Dolutegravir bests darunavir in first-line HIV setting
This article was originally published in Scrip
Executive Summary
Initial results from an ongoing multinational, open label trial within a suite of studies for ViiV Healthcare's dolutegravir have bolstered evidence of efficacy for the integrase strand transfer inhibitor in the first-line treatment of HIV.